Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Haematology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Haematology Other
    X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - (N Engl J Med)
    Postoperative Anticoagulation Therapy Necessary in Patients Following Major Surgery: Presented at ASA - (DGDispatch)
    New USP Standards for Heparin Products Will Result in Decreased Potency - (DGNews)
    Thrombomodulin mutations in atypical hemolytic-uremic syndrome - (N Engl J Med)
    Circulating Blood Cells Are Important Predictors of Cancer Spread in Children - (DGNews)

    News archive

     Recent webcasts/CME - Haematology Other
    • Managing Treatment- and Disease-Related Complications in Multiple Myeloma
    • Thrombosis in Multiple Myeloma: Choice of Thromboprophylaxis Depends on Type of Therapy and Individual Risk of Patient
    • Peripheral Neuropathy in Multiple Myeloma: Early Recognition and Intervention Key to Minimize Long-Term Complications
    • Myeloma Bone Disease: Is Targeting of Osteoclastic and Osteoblastic Mechanisms Necessary for Effective Therapy?
    • PreAnesthetic Assessment of the Patient on Low Dose Aspirin and a Thienopyridine - Part 1

      Webcasts/CME archive

       Recent cases - Haematology Other
        Cobalamin Deficiency Resulting in a Rare Haematological Disorder: A Case Report
        Complications of Evans' Syndrome in an Infant with Hereditary Spherocytosis: A Case Report
        Multisystem Failure Due to Three Coexisting Autoimmune Diseases
        An Unusual Cause of Methaemoglobinaemia
        Vancomycin-Induced Thrombocytopenia in a 60-Year-Old Man: A Case Report

        Cases archive
          




        my personal edition > haematology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Blunt Trauma Patients Who Receive Recombinant Activated Factor VIIa Show Lower Mortality: Presented at ISTH

          By Bruce Sylvester

          GENEVA, SWITZERLAND -- July 11, 2007 -- Mortality is significantly reduced in trauma and surgical patients with massive haemorrhage who receive recombinant activated coagulation Factor VIIa (rFVIIa, Novoseven®) compared with mortality predictions made using standard scoring systems before the start of this treatment.

          Researchers reported this finding here on July 8th at the 21st Congress of the International Society of Thrombosis and Haemostasis (ISTH).

          "We have seen some data indicating the possible efficacy of the off-label use of recombinant activated Factor VIIa in this kind of medical situation, but it has not been tested before," says lead investigator and presenter Jurgen Koscielny, MD, Assistant Professor of Transfusion Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.

          Dr. Koscielny and colleagues evaluated the clinical efficacy of rFVII a in a group of 45 patients (36 trauma, 9 surgery), aged 16 to 78 years, with severe massive haemorrhage requiring over 16 transfusion units of packed red blood cells with rFVIIa (median dosage 90 mcg/kg).

          Dr. Koscielny and colleagues assessed each subject for post-rFVIIa blood loss and transfusion requirements, and compared actual mortality outcomes with the predicted outcomes derived from the TRauma Injury Severity Score (TRISS) and Physiological and Operative Severity Score for enUmeration of Mortality and morbidity (POSSUM) scoring systems.

          Results showed that blood loss was markedly reduced in 93% of the 45 subjects, and transfusion requirements also decreased after rFVIIa administration.

          Notably, actual mortality was 31.4% of 35 trauma patients versus a TRISS prediction of 58.4% and a POSSUM prediction of 62%.

          Among surgical patients, actual mortality was 33.3% versus a POSSUM prediction of 44%. Mortality for all patients was 31.1% versus the POSSUM prediction of 59%.

          "Mortality was greatly reduced in this group of trauma and surgical patients who had massive haemorrhage when compared with predictions using the TRISS or POSSUM scoring systems. This may be associated with the use of rFVIIa," the authors conclude.


          [Presentation title: Efficacy and Safety of Recombinant Activated Factor VII (Novoseven) in Trauma and Surgery Patients With Massive Bleeding - A Register Analysis. Poster P-S-229]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send